{"url_path":"/sec/sxtp/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBITS","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1946563/0001554855-26-001058-index.html","accession_number":"0001554855-26-001058","cik":"0001946563","ticker":"SXTP","issuer_name":"60 DEGREES PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1946563/0001554855-26-001058-index.html","primary_entity_key":"0001946563","primary_entity_name":"60 DEGREES PHARMACEUTICALS, INC."},"word_count":556,"has_tables":true,"body_markdown":"ITEM 6. EXHIBITS\n\n \n\nEXHIBIT INDEX\n\n \n\nExhibit No.\n\n \n\nDescription\n\n1.1\n\n \n\n[Engagement Agreement (incorporated by reference to Exhibit 1.1 of the Company’s Current Report on Form 8-K filed on January 30, 2025](https://www.sec.gov/Archives/edgar/data/1946563/000121390025008463/ea022931001ex1-1_60degrees.htm))\n\n1.2\n\n \n\n[Amendment to Engagement Agreement (incorporated by reference to Exhibit 1.2 of the Company’s Current Report on Form 8-K filed on January 30, 2025)](https://www.sec.gov/Archives/edgar/data/1946563/000121390025008463/ea022931001ex1-2_60degrees.htm)\n\n1.3\n\n \n\n[Extension to Engagement Agreement (incorporated by reference to Exhibit 1.3 of the Company’s Current Report on Form 8-K filed on January 30, 2025)](https://www.sec.gov/Archives/edgar/data/1946563/000121390025008463/ea022931001ex1-3_60degrees.htm)\n\n1.4\n\n \n\n[Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed July 18, 2025)](https://www.sec.gov/Archives/edgar/data/1946563/000121390025065718/ea024943801ex10-1_60degrees.htm)\n\n1.5\n\n \n\n[Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.4 of the Company’s Current Report on Form 8-K filed July 18, 2025)](https://www.sec.gov/Archives/edgar/data/1946563/000121390025065718/ea024943801ex4-4_60degrees.htm)\n\n1.6\n\n \n\n[At-The-Market Sales Agreement (incorporated by reference to Exhibit 1.1 of the Company’s Current Report on Form 8-K filed September 5, 2025)](https://www.sec.gov/Archives/edgar/data/1946563/000121390025085040/ea025591601ex1-1_60degrees.htm)\n\n4.1\n\n \n\n[Form of Warrant (incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed on January 30, 2025)](https://www.sec.gov/Archives/edgar/data/1946563/000121390025008463/ea022931001ex4-1_60degrees.htm)\n\n4.2\n\n \n\n[Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.2 of the Company’s Current Report on Form 8-K filed on January 30, 2025)](https://www.sec.gov/Archives/edgar/data/1946563/000121390025008463/ea022931001ex4-2_60degrees.htm)\n\n4.3\n\n \n\n[Form of Warrant (incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed on February 6, 2025)](https://www.sec.gov/Archives/edgar/data/1946563/000121390025010962/ea023022801ex4-1_60degrees.htm)\n\n4.4\n\n \n\n[Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.2 of the Company’s Current Report on Form 8-K filed on February 6, 2025)](https://www.sec.gov/Archives/edgar/data/1946563/000121390025010962/ea023022801ex4-2_60degrees.htm)\n\n10.1\n\n \n\n[Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed on January 30, 2025)](https://www.sec.gov/Archives/edgar/data/1946563/000121390025008463/ea022931001ex10-1_60degrees.htm)\n\n10.2\n\n \n\n[Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed on February 6, 2025)](https://www.sec.gov/Archives/edgar/data/1946563/000121390025010962/ea023022801ex10-1_60degrees.htm)\n\n31.1*\n\n \n\n[Rule 13a-14(a)/15d-14(a) Certification of the President and Chief Executive Officer of 60 Degrees Pharmaceuticals, Inc.](ex311_1.htm)\n\n31.2*\n\n \n\n[Rule 13a-14(a)/15d-14(a) Certification of the Chief Financial Officer of 60 Degrees Pharmaceuticals, Inc.](ex312_2.htm)\n\n32.1**\n\n \n\n[Section 1350 Certification of the President and Chief Executive Officer of 60 Degrees Pharmaceuticals, Inc.](ex321_3.htm)\n\n32.2**\n\n \n\n[Section 1350 Certification of the Chief Financial Officer of 60 Degrees Pharmaceuticals, Inc.](ex322_4.htm)\n\n101.INS*\n\n \n\nInline XBRL Instance Document\n\n101.SCH*\n\n \n\nInline XBRL Taxonomy Extension Schema Document\n\n101.CAL*\n\n \n\nInline XBRL Taxonomy Extension Calculation Linkbase Document\n\n101.DEF*\n\n \n\nInline XBRL Taxonomy Extension Definition Linkbase Document\n\n101.LAB*\n\n \n\nInline XBRL Taxonomy Extension Label Linkbase Document\n\n101.PRE*\n\n \n\nInline XBRL Taxonomy Extension Presentation Linkbase Document\n\n104*\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n*\n\nFiled herewith.\n\n \n\n**\n\nExhibits 32.1 and 32.2 are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall such exhibits be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise specifically stated in such filing.\n\n \n\n37\n\nSIGNATURES\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n60 DEGREES PHARMACEUTICALS, INC.\n\n \n\n \n\nDated: May 15, 2026\n\n/s/ Geoffrey Dow\n\n \n\nGeoffrey Dow\n\n \n\nChief Executive Officer and President, Director\n\n(Principal Executive Officer)\n\n \n\n \n\nDated: May 15, 2026\n\n/s/ Tyrone Miller\n\n \n\nTyrone Miller\n\n \n\nChief Financial Officer\n\n(Principal Financial and Accounting Officer)\n\n \n\n38"}